These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 24245760)

  • 1. Can mycobacterial genomics generate novel targets as speed-breakers against the race for drug resistance.
    Chauhan RS; Chanumolu SK; Rout C; Shrivastava R
    Curr Pharm Des; 2014; 20(27):4319-45. PubMed ID: 24245760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
    Tomioka H
    Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Machine learning and tubercular drug target recognition.
    Fu LM
    Curr Pharm Des; 2014; 20(27):4307-18. PubMed ID: 24245763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent developments in genomics, bioinformatics and drug discovery to combat emerging drug-resistant tuberculosis.
    Swaminathan S; Sundaramurthi JC; Palaniappan AN; Narayanan S
    Tuberculosis (Edinb); 2016 Dec; 101():31-40. PubMed ID: 27865394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification and characterization of potential druggable targets among hypothetical proteins of extensively drug resistant Mycobacterium tuberculosis (XDR KZN 605) through subtractive genomics approach.
    Uddin R; Siddiqui QN; Azam SS; Saima B; Wadood A
    Eur J Pharm Sci; 2018 Mar; 114():13-23. PubMed ID: 29174549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systems-level modeling of mycobacterial metabolism for the identification of new (multi-)drug targets.
    Rienksma RA; Suarez-Diez M; Spina L; Schaap PJ; Martins dos Santos VA
    Semin Immunol; 2014 Dec; 26(6):610-22. PubMed ID: 25453232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A whole genome bioinformatic approach to determine potential latent phase specific targets in Mycobacterium tuberculosis.
    Defelipe LA; Do Porto DF; Pereira Ramos PI; Nicolás MF; Sosa E; Radusky L; Lanzarotti E; Turjanski AG; Marti MA
    Tuberculosis (Edinb); 2016 Mar; 97():181-92. PubMed ID: 26791267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DFT based QSAR/QSPR models in the development of novel anti-tuberculosis drugs targeting Mycobacterium tuberculosis.
    Rajkhowa S; Deka RC
    Curr Pharm Des; 2014; 20(27):4455-73. PubMed ID: 24245759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting tuberculosis: a glimpse of promising drug targets.
    Arora N; Banerjee AK
    Mini Rev Med Chem; 2012 Mar; 12(3):187-201. PubMed ID: 22356190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Frontier of mycobacterium research--host vs. mycobacterium].
    Okada M; Shirakawa T
    Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single nucleotide polymorphisms may explain the contrasting phenotypes of two variants of a multidrug-resistant Mycobacterium tuberculosis strain.
    Bigi MM; Lopez B; Blanco FC; Sasiain MD; De la Barrera S; Marti MA; Sosa EJ; Fernández Do Porto DA; Ritacco V; Bigi F; Soria MA
    Tuberculosis (Edinb); 2017 Mar; 103():28-36. PubMed ID: 28237031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Whole-Transcriptome and -Genome Analysis of Extensively Drug-Resistant Mycobacterium tuberculosis Clinical Isolates Identifies Downregulation of
    de Welzen L; Eldholm V; Maharaj K; Manson AL; Earl AM; Pym AS
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28993337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug-resistant tuberculosis among previously treated patients in Yangon, Myanmar.
    Tun T; Nyunt WW; Latt KZ; Samaranayaka A; Crump JA; Thinn KK; Cook GM; Aung HL
    Int J Mycobacteriol; 2016 Sep; 5(3):366-367. PubMed ID: 27847028
    [No Abstract]   [Full Text] [Related]  

  • 15. [Recent progress in mycobacteriology].
    Okada M; Kobayashi K
    Kekkaku; 2007 Oct; 82(10):783-99. PubMed ID: 18018602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of glucosyl-3-phosphoglycerate phosphatase as a novel drug target against resistant strain of Mycobacterium tuberculosis (XDR1219) by using comparative metabolic pathway approach.
    Uddin R; Zahra NU; Azam SS
    Comput Biol Chem; 2019 Apr; 79():91-102. PubMed ID: 30743161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genomic plasticity between human and mycobacterial DNA: A review.
    Danjuma L; Ling MP; Hamat RA; Higuchi A; Alarfaj AA; Marlina ; Benelli G; Arulselvan P; Rajan M; Kumar Subbiah S
    Tuberculosis (Edinb); 2017 Dec; 107():38-47. PubMed ID: 29050770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of a novel inhibitor of isocitrate lyase as a potent antitubercular agent against both active and non-replicating Mycobacterium tuberculosis.
    Liu Y; Zhou S; Deng Q; Li X; Meng J; Guan Y; Li C; Xiao C
    Tuberculosis (Edinb); 2016 Mar; 97():38-46. PubMed ID: 26980494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New approaches to tuberculosis--novel drugs based on drug targets related to toll-like receptors in macrophages.
    Tomioka H
    Curr Pharm Des; 2014; 20(27):4404-17. PubMed ID: 24245765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Latent tuberculosis: is there a role for thioridazine?
    Sohaskey C
    Recent Pat Antiinfect Drug Discov; 2011 May; 6(2):139-46. PubMed ID: 21548878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.